Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.56 |
| ▸ | NPC1 | O15118 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | MAOB | P27338 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | METAP2 | P50579 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6353681 | 0.90 | KMT2A (0.64) | RAB9ANPC1LMNASMN1; SMN2KMT2A | |
| SCHEMBL6351810 | 0.89 | KMT2A (0.52) | LMNASMN1; SMN2KMT2AMEN1ALDH1A1 | |
| SCHEMBL6353696 | 0.88 | PTGES (0.56) | RAB9ANPC1LMNASMN1; SMN2KMT2A | |
| SCHEMBL6357750 | 0.87 | POLB (0.59) | RAB9ANPC1LMNASMN1; SMN2KMT2A | |
| SCHEMBL6437241 | 0.86 | RPA1 (0.64) | RAB9ANPC1LMNASMN1; SMN2KMT2A | |
| SCHEMBL6830408 | 0.85 | SMN1; SMN2 (0.48) | RAB9ANPC1LMNASMN1; SMN2KMT2A | |
| SCHEMBL6349460 | 0.85 | MEN1 (0.60) | KMT2AMEN1METAP2 | |
| SCHEMBL6358855 | 0.84 | MAPT (0.57) | RAB9ANPC1LMNASMN1; SMN2KMT2A | |
| SCHEMBL6350610 | 0.82 | MEN1 (0.69) | KMT2AMEN1METAP2 | |
| SCHEMBL6348358 | 0.82 | METAP2 (0.71) | LMNASMN1; SMN2KMT2AMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050113450-A1 | Antibacterial agents | PHARMACIA & UPJOHN COMPANY | 2005-05-26 | — | — | US | claimed |
| WO-2004018414-A2 | ANTIBACTERIAL AGENTS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-03-04 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113450-A1 | Antibacterial agents | CLPP, SPOUT1, SAMHD1 | RAB9A 3062/4885NPC1 3512/4885LMNA 4552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.